PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn't considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.

Full Report Details at
- http://www.fastmr.com/prod/642937_pharmapoint_dermatophytic_onychomycosis_do_us.aspx?afid=301

Highlights

Key Questions Answered

* How big of an impact will topical agents have on the DO market? What do key opinion leaders think of this paradigm shift?
* What new product is expected to become the market leader during the forecast period? How will this impact the existing generic therapies?
* How will a change in the route of administration change the uptake of drugs in the US market?
* What are the primary unmet needs that exist in the market according to key opinion leaders?
* What alliance opportunities exist in this market for a company looking to tap into the DO market?

Key Findings

* Generic therapies are expected to pose as a considerable threat to upcoming topical therapies because of their shorter treatment duration.
* The first wave of new pipeline candidates will increase drug treatment rates as physicians begin to opt for more safer options for treatment.
* Individual compliance, patient co-morbidities, and insurance payers function as important considerations in assessing the treatment algorithm for every patient.

Scope

* Overview of DO, including epidemiology, etiology, general symptoms from infection, and disease management recommendations and guidelines.
* Annualized DO market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO market.
* Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically new therapies with novel routes of administration.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022